PRIMARY BILIARY CHOLANGITIS TREATMENT MARKET ANALYSIS

Market News

Recent Developments

Primary Biliary Cholangitis Treatment Market

• On June 30 2023, Ipsen Pharma, a biopharmaceutical company, and GENFIT, a biopharmaceutical group, announced positive topline data from the pivotal ELATIVE Phase III trial. In the trial the efficacy and safety of elafibranor, an investigational dual α, δ PPAR agonist, is being assessed for the treatment of patients with the rare cholestatic liver disease, primary biliary cholangitis (PBC), who have an inadequate response or intolerance to the current standard of care therapy, ursodeoxycholic acid (UDCA).
• In January 2022, COUR Pharmaceuticals, a biotechnology company developing novel immune-modifying nanoparticles (CNPs) to treat immune disorders, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the company's investigational therapy, CNP-104 for the treatment of primary biliary cholangitis.

Agreements and collaborations

• In December 2021, Ipsen Pharma and GENFIT, a biopharmaceutical group, announced that the companies have entered into a long-term strategic partnership for global collaboration between the two companies. The agreement gives Ipsen Pharma exclusive worldwide license to develop, manufacture, and commercialize GENFIT’s investigational treatment elafibranor, for people living with Primary Biliary Cholangitis (PBC).
• In November 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, announced that it is expanding its pipeline by entering into a collaboration and license option agreement with COUR Pharmaceuticals, a biotechnology company. This agreement gives Ironwood an option to acquire an exclusive license to develop and commercialize, in the U.S., COUR’s investigational therapy, CNP-104 (the “License”), which if successful, could transform the treatment of primary biliary cholangitis.